- Home
- CVAC vs REAL Comparison
CVAC vs REAL Comparison
Compare CVAC & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- REAL
- Stock Information
- Founded
- CVAC 2000
- REAL 2011
- Country
- CVAC Germany
- REAL United States
- Employees
- CVAC N/A
- REAL N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- REAL Other Specialty Stores
- Sector
- CVAC Health Care
- REAL Consumer Discretionary
- Exchange
- CVAC Nasdaq
- REAL Nasdaq
- Market Cap
- CVAC 1.2B
- REAL 1.4B
- IPO Year
- CVAC 2020
- REAL 2019
- Fundamental
- Price
- CVAC $5.34
- REAL $14.80
- Analyst Decision
- CVAC Hold
- REAL Buy
- Analyst Count
- CVAC 3
- REAL 8
- Target Price
- CVAC $6.83
- REAL $13.94
- AVG Volume (30 Days)
- CVAC 574.2K
- REAL 4.6M
- Earning Date
- CVAC 11-12-2025
- REAL 11-10-2025
- Dividend Yield
- CVAC N/A
- REAL N/A
- EPS Growth
- CVAC N/A
- REAL N/A
- EPS
- CVAC 1.01
- REAL N/A
- Revenue
- CVAC $599,540,810.00
- REAL $662,789,000.00
- Revenue This Year
- CVAC N/A
- REAL $14.56
- Revenue Next Year
- CVAC $23.40
- REAL $10.14
- P/E Ratio
- CVAC $5.32
- REAL N/A
- Revenue Growth
- CVAC 675.15
- REAL 14.30
- 52 Week Low
- CVAC $2.37
- REAL $3.70
- 52 Week High
- CVAC $5.72
- REAL $16.24
- Technical
- Relative Strength Index (RSI)
- CVAC 51.18
- REAL 69.01
- Support Level
- CVAC $5.17
- REAL $10.49
- Resistance Level
- CVAC $5.41
- REAL $12.22
- Average True Range (ATR)
- CVAC 0.05
- REAL 0.87
- MACD
- CVAC -0.00
- REAL 0.21
- Stochastic Oscillator
- CVAC 70.82
- REAL 74.00
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.